Cargando…
Febuxostat versus allopurinol for patients with gout: is it time to overcome concerns regarding cardiovascular safety?
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8768035/ https://www.ncbi.nlm.nih.gov/pubmed/35079188 http://dx.doi.org/10.5114/reum.2021.111698 |
| _version_ | 1784634832099213312 |
|---|---|
| author | Patoulias, Dimitrios Ioannis Doumas, Michael |
| author_facet | Patoulias, Dimitrios Ioannis Doumas, Michael |
| author_sort | Patoulias, Dimitrios Ioannis |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8768035 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-87680352022-01-24 Febuxostat versus allopurinol for patients with gout: is it time to overcome concerns regarding cardiovascular safety? Patoulias, Dimitrios Ioannis Doumas, Michael Reumatologia Letter to the Editor Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie 2021-12-09 2021 /pmc/articles/PMC8768035/ /pubmed/35079188 http://dx.doi.org/10.5114/reum.2021.111698 Text en Copyright: © 2021 Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie https://creativecommons.org/licenses/by-nc-sa/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license. |
| spellingShingle | Letter to the Editor Patoulias, Dimitrios Ioannis Doumas, Michael Febuxostat versus allopurinol for patients with gout: is it time to overcome concerns regarding cardiovascular safety? |
| title | Febuxostat versus allopurinol for patients with gout: is it time to overcome concerns regarding cardiovascular safety? |
| title_full | Febuxostat versus allopurinol for patients with gout: is it time to overcome concerns regarding cardiovascular safety? |
| title_fullStr | Febuxostat versus allopurinol for patients with gout: is it time to overcome concerns regarding cardiovascular safety? |
| title_full_unstemmed | Febuxostat versus allopurinol for patients with gout: is it time to overcome concerns regarding cardiovascular safety? |
| title_short | Febuxostat versus allopurinol for patients with gout: is it time to overcome concerns regarding cardiovascular safety? |
| title_sort | febuxostat versus allopurinol for patients with gout: is it time to overcome concerns regarding cardiovascular safety? |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8768035/ https://www.ncbi.nlm.nih.gov/pubmed/35079188 http://dx.doi.org/10.5114/reum.2021.111698 |
| work_keys_str_mv | AT patouliasdimitriosioannis febuxostatversusallopurinolforpatientswithgoutisittimetoovercomeconcernsregardingcardiovascularsafety AT doumasmichael febuxostatversusallopurinolforpatientswithgoutisittimetoovercomeconcernsregardingcardiovascularsafety |